David H. Eidelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David H. Eidelman has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn J. Baglole
Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada
11 shared publications - Qutayba Hamid
Research Institute of Medical and Health Sciences, University of Sharjah, P.O. Box 27272, Sharjah, United Arab Emirates.
4 shared publications - Jean Bourbeau
Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Quebec, Canada
3 shared publications - Andrea Benedetti
McGill University
2 shared publications - Emily T. Wilson
Department of Pharmacology and Therapeutics, McGill University
2 shared publications - Hussein Traboulsi
Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
2 shared publications
Latest Publications
- 20 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68102
In vitro Cannabis Exposures of Lung Epithelial Cells at the Air-Liquid Interface
Cannabis is used by an estimated 192 million people around the world. Most people use cannabis through the inhalation of cannabis smoke, which contains combustion by-products that can negatively affect lung health. Knowledge of these risks has led to a growing interest in cannabis vaporizers, which heat the dry cannabis flower without burning. Vaporizing cannabis still releases cannabinoids for inhalation but heats the plant material at a lower temperature. There is currently no standardized in vitro model for assessing the effects of dry cannabis vapor. Therefore, we established a model for the exposure of lung cell cultures at an air-liquid interface (ALI), whereby cells are apically exposed to vaporized cannabis, thereby more accurately simulating lung epithelial cell physiology. This protocol ensures consistent and reproducible delivery of cannabis vapor to the cell surface, providing a reliable platform for investigating the cellular and molecular impacts of vaporized cannabis. This work is the first to standardize an in vitro cannabis vapor delivery method, which can serve as a benchmark for future preclinical cannabis research.
- 20 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68102
In vitro Cannabis Exposures of Lung Epithelial Cells at the Air-Liquid Interface
Cannabis is used by an estimated 192 million people around the world. Most people use cannabis through the inhalation of cannabis smoke, which contains combustion by-products that can negatively affect lung health. Knowledge of these risks has led to a growing interest in cannabis vaporizers, which heat the dry cannabis flower without burning. Vaporizing cannabis still releases cannabinoids for inhalation but heats the plant material at a lower temperature. There is currently no standardized in vitro model for assessing the effects of dry cannabis vapor. Therefore, we established a model for the exposure of lung cell cultures at an air-liquid interface (ALI), whereby cells are apically exposed to vaporized cannabis, thereby more accurately simulating lung epithelial cell physiology. This protocol ensures consistent and reproducible delivery of cannabis vapor to the cell surface, providing a reliable platform for investigating the cellular and molecular impacts of vaporized cannabis. This work is the first to standardize an in vitro cannabis vapor delivery method, which can serve as a benchmark for future preclinical cannabis research.
- 30 May 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 219,p. e68094
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Despite their growing popularity, cannabis vape products remain understudied. Cannabis vape cartridges are used with battery-powered devices that aerosolize cannabis flower extracts containing high concentrations of cannabinoids such as THC. These types of products are commonly known as cannabis distillates. The potency of these products presents challenges in establishing effective dosing for preclinical studies. Currently, there are no established, standardized preclinical models for testing the safety and efficacy of these products in ways analogous to human use patterns. Thus, the in vivo cannabis distillate exposure regime required to achieve physiologically relevant doses in comparison to what is achieved in humans remains undetermined. To address this gap, a standardized preclinical murine model for inhalation of vaporized cannabis distillates has been developed using a computer-controlled delivery system. This protocol details procedures to administer cannabis vape distillates using a regimented puff topography to mice by a nose-only exposure tower. Methods to monitor mouse behavioral outcomes post-exposure and the utilization of a semi-quantitative ELISA to confirm THC delivery into the systemic circulation are also provided. This protocol will allow for the investigation of the pulmonary and systemic responses to cannabis vape distillate products by researchers interested in exploring the impact of cannabis vaping using real-world delivery protocols, thereby providing an opportunity for rigorous safety and therapeutic evaluation.
- 30 May 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 219,p. e68094
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Despite their growing popularity, cannabis vape products remain understudied. Cannabis vape cartridges are used with battery-powered devices that aerosolize cannabis flower extracts containing high concentrations of cannabinoids such as THC. These types of products are commonly known as cannabis distillates. The potency of these products presents challenges in establishing effective dosing for preclinical studies. Currently, there are no established, standardized preclinical models for testing the safety and efficacy of these products in ways analogous to human use patterns. Thus, the in vivo cannabis distillate exposure regime required to achieve physiologically relevant doses in comparison to what is achieved in humans remains undetermined. To address this gap, a standardized preclinical murine model for inhalation of vaporized cannabis distillates has been developed using a computer-controlled delivery system. This protocol details procedures to administer cannabis vape distillates using a regimented puff topography to mice by a nose-only exposure tower. Methods to monitor mouse behavioral outcomes post-exposure and the utilization of a semi-quantitative ELISA to confirm THC delivery into the systemic circulation are also provided. This protocol will allow for the investigation of the pulmonary and systemic responses to cannabis vape distillate products by researchers interested in exploring the impact of cannabis vaping using real-world delivery protocols, thereby providing an opportunity for rigorous safety and therapeutic evaluation.
- 30 May 2025
- Published by MyJove Corporation
- No. 219,p. e68094
JoVE Video Dataset
Despite their growing popularity, cannabis vape products remain understudied. Cannabis vape cartridges are used with battery-powered devices that aerosolize cannabis flower extracts containing high concentrations of cannabinoids such as THC. These types of products are commonly known as cannabis distillates. The potency of these products presents challenges in establishing effective dosing for preclinical studies. Currently, there are no established, standardized preclinical models for testing the safety and efficacy of these products in ways analogous to human use patterns. Thus, the in vivo cannabis distillate exposure regime required to achieve physiologically relevant doses in comparison to what is achieved in humans remains undetermined. To address this gap, a standardized preclinical murine model for inhalation of vaporized cannabis distillates has been developed using a computer-controlled delivery system. This protocol details procedures to administer cannabis vape distillates using a regimented puff topography to mice by a nose-only exposure tower. Methods to monitor mouse behavioral outcomes post-exposure and the utilization of a semi-quantitative ELISA to confirm THC delivery into the systemic circulation are also provided. This protocol will allow for the investigation of the pulmonary and systemic responses to cannabis vape distillate products by researchers interested in exploring the impact of cannabis vaping using real-world delivery protocols, thereby providing an opportunity for rigorous safety and therapeutic evaluation.
- 30 May 2025
- Published by MyJove Corporation
- No. 219,p. e68094
JoVE Video Dataset
Despite their growing popularity, cannabis vape products remain understudied. Cannabis vape cartridges are used with battery-powered devices that aerosolize cannabis flower extracts containing high concentrations of cannabinoids such as THC. These types of products are commonly known as cannabis distillates. The potency of these products presents challenges in establishing effective dosing for preclinical studies. Currently, there are no established, standardized preclinical models for testing the safety and efficacy of these products in ways analogous to human use patterns. Thus, the in vivo cannabis distillate exposure regime required to achieve physiologically relevant doses in comparison to what is achieved in humans remains undetermined. To address this gap, a standardized preclinical murine model for inhalation of vaporized cannabis distillates has been developed using a computer-controlled delivery system. This protocol details procedures to administer cannabis vape distillates using a regimented puff topography to mice by a nose-only exposure tower. Methods to monitor mouse behavioral outcomes post-exposure and the utilization of a semi-quantitative ELISA to confirm THC delivery into the systemic circulation are also provided. This protocol will allow for the investigation of the pulmonary and systemic responses to cannabis vape distillate products by researchers interested in exploring the impact of cannabis vaping using real-world delivery protocols, thereby providing an opportunity for rigorous safety and therapeutic evaluation.
- Open Access
- 8 March 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-18
Transcriptomic changes in oxidative stress, immunity, and cancer pathways caused by cannabis vapor on alveolar epithelial cells
As legalization of cannabis increases worldwide, vaping cannabis is gaining popularity due to the belief that it is less harmful than smoking cannabis. However, the safety of cannabis vaping remains untested. To address this, we developed a physiologically relevant method for in vitro assessment of cannabis vapor on alveolar epithelial cell cultures. We compared the transcriptional response in three in vitro models of cannabis vapor exposure using A549 epithelial cells in submerged culture, pseudo-air liquid interface (ALI) culture, and ALI culture coupled with the expoCube™ advanced exposure system. Baseline gene expression in ALI-maintained A549 cells showed higher expression of type 2 alveolar epithelial (AEC2) genes related to surfactant production, ion movement, and barrier integrity. Acute exposure to cannabis vapor significantly affected gene expression in AEC2 cells belonging to pathways related to cancer, oxidative stress, and the immune response without being associated with a DNA damage response. This study identifies potential risks of cannabis vaping and underscores the need for further exploration into its respiratory health implications. Graphical Abstract • Vaporizing cannabis is increasingly popular but remains largely untested. • We used three in vitro models to assess the effects of cannabis vapor on alveolar epithelial cells. • Cannabis vapor exposure alters pathways linked to cancer and metabolism, without causing DNA damage.
- 8 March 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-18
Open AccessTranscriptomic changes in oxidative stress, immunity, and cancer pathways caused by cannabis vapor on alveolar epithelial cells
As legalization of cannabis increases worldwide, vaping cannabis is gaining popularity due to the belief that it is less harmful than smoking cannabis. However, the safety of cannabis vaping remains untested. To address this, we developed a physiologically relevant method for in vitro assessment of cannabis vapor on alveolar epithelial cell cultures. We compared the transcriptional response in three in vitro models of cannabis vapor exposure using A549 epithelial cells in submerged culture, pseudo-air liquid interface (ALI) culture, and ALI culture coupled with the expoCube™ advanced exposure system. Baseline gene expression in ALI-maintained A549 cells showed higher expression of type 2 alveolar epithelial (AEC2) genes related to surfactant production, ion movement, and barrier integrity. Acute exposure to cannabis vapor significantly affected gene expression in AEC2 cells belonging to pathways related to cancer, oxidative stress, and the immune response without being associated with a DNA damage response. This study identifies potential risks of cannabis vaping and underscores the need for further exploration into its respiratory health implications. Graphical Abstract • Vaporizing cannabis is increasingly popular but remains largely untested. • We used three in vitro models to assess the effects of cannabis vapor on alveolar epithelial cells. • Cannabis vapor exposure alters pathways linked to cancer and metabolism, without causing DNA damage.
- Open Access
- 18 September 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002423
Sex-specific alterations in pulmonary metabolic, xenobiotic and lipid signalling pathways after e-cigarette aerosol exposure during adolescence in mice
Background: E-cigarette use is now prevalent among adolescents and young adults, raising concerns over potential adverse long-term health effects. Although it is hypothesised that e-cigarettes promote inflammation, studies have yielded conflicting evidence. Our previous work showed that JUUL, a popular e-cigarette brand, elicited minimal lung inflammation but induced significant molecular changes in adult C57BL/6 mice. Methods: Now, we have profiled immunological and proteomic changes in the lungs of adolescent male and female BALB/c and C57BL/6 mice exposed to a flavoured JUUL aerosol containing 18 mg/mL of nicotine for 14 consecutive days. We evaluated changes in the immune composition by flow cytometry, gene expression levels by reverse transcription-quantitative PCR and assessed the proteomic profile of the lungs and bronchoalveolar lavage (BAL) by tandem mass tag-labelled mass spectroscopy. Results: While there were few significant changes in the immune composition of the lungs, proteomic analysis revealed that JUUL exposure caused significant sex-dependent and strain-dependent differences in lung and BAL proteins that are implicated in metabolic pathways, including those related to lipids and atherosclerosis, as well as pathways related to immune function and response to xenobiotics. Notably, these changes were more pronounced in male mice. Conclusions: These findings raise the possibility that vaping dysregulates numerous biological responses in lungs that may affect disease risk, disproportionally impacting males and raising significant concerns for the future health of male youth who currently vape.
- 18 September 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002423
Open AccessSex-specific alterations in pulmonary metabolic, xenobiotic and lipid signalling pathways after e-cigarette aerosol exposure during adolescence in mice
Background: E-cigarette use is now prevalent among adolescents and young adults, raising concerns over potential adverse long-term health effects. Although it is hypothesised that e-cigarettes promote inflammation, studies have yielded conflicting evidence. Our previous work showed that JUUL, a popular e-cigarette brand, elicited minimal lung inflammation but induced significant molecular changes in adult C57BL/6 mice. Methods: Now, we have profiled immunological and proteomic changes in the lungs of adolescent male and female BALB/c and C57BL/6 mice exposed to a flavoured JUUL aerosol containing 18 mg/mL of nicotine for 14 consecutive days. We evaluated changes in the immune composition by flow cytometry, gene expression levels by reverse transcription-quantitative PCR and assessed the proteomic profile of the lungs and bronchoalveolar lavage (BAL) by tandem mass tag-labelled mass spectroscopy. Results: While there were few significant changes in the immune composition of the lungs, proteomic analysis revealed that JUUL exposure caused significant sex-dependent and strain-dependent differences in lung and BAL proteins that are implicated in metabolic pathways, including those related to lipids and atherosclerosis, as well as pathways related to immune function and response to xenobiotics. Notably, these changes were more pronounced in male mice. Conclusions: These findings raise the possibility that vaping dysregulates numerous biological responses in lungs that may affect disease risk, disproportionally impacting males and raising significant concerns for the future health of male youth who currently vape.
- Open Access
Role of Human Antigen R (HuR) in the Regulation of Pulmonary ACE2 Expression
Patients with COPD may be at an increased risk for severe illness from COVID-19 because of ACE2 upregulation, the entry receptor for SARS-CoV-2. Chronic exposure to cigarette smoke, the main risk factor for COPD, increases pulmonary ACE2. How ACE2 expression is controlled is not known but may involve HuR, an RNA binding protein that increases protein expression by stabilizing mRNA. We hypothesized that HuR would increase ACE2 protein expression. We analyzed scRNA-seq data to profile ELAVL1 expression in distinct respiratory cell populations in COVID-19 and COPD patients. HuR expression and cellular localization was evaluated in COPD lung tissue by multiplex immunohistochemistry and in human lung cells by imaging flow cytometry. The regulation of ACE2 expression was evaluated using siRNA-mediated knockdown of HuR. There is a significant positive correlation between ELAVL1 and ACE2 in COPD cells. HuR cytoplasmic localization is higher in smoker and COPD lung tissue; there were also higher levels of cleaved HuR (CP-1). HuR binds to ACE2 mRNA but knockdown of HuR does not change ACE2 protein levels in primary human lung fibroblasts (HLFs). Our work is the first to investigate the association between ACE2 and HuR. Further investigation is needed to understand the mechanistic underpinning behind the regulation of ACE2 expression.
Open AccessRole of Human Antigen R (HuR) in the Regulation of Pulmonary ACE2 Expression
Patients with COPD may be at an increased risk for severe illness from COVID-19 because of ACE2 upregulation, the entry receptor for SARS-CoV-2. Chronic exposure to cigarette smoke, the main risk factor for COPD, increases pulmonary ACE2. How ACE2 expression is controlled is not known but may involve HuR, an RNA binding protein that increases protein expression by stabilizing mRNA. We hypothesized that HuR would increase ACE2 protein expression. We analyzed scRNA-seq data to profile ELAVL1 expression in distinct respiratory cell populations in COVID-19 and COPD patients. HuR expression and cellular localization was evaluated in COPD lung tissue by multiplex immunohistochemistry and in human lung cells by imaging flow cytometry. The regulation of ACE2 expression was evaluated using siRNA-mediated knockdown of HuR. There is a significant positive correlation between ELAVL1 and ACE2 in COPD cells. HuR cytoplasmic localization is higher in smoker and COPD lung tissue; there were also higher levels of cleaved HuR (CP-1). HuR binds to ACE2 mRNA but knockdown of HuR does not change ACE2 protein levels in primary human lung fibroblasts (HLFs). Our work is the first to investigate the association between ACE2 and HuR. Further investigation is needed to understand the mechanistic underpinning behind the regulation of ACE2 expression.
- Open Access
- 30 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (23) , 12955
Involvement of the ACE2/Ang-(1–7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19
Pulmonary fibrosis is a chronic, fibrotic lung disease affecting 3 million people worldwide. The ACE2/Ang-(1–7)/MasR axis is of interest in pulmonary fibrosis due to evidence of its anti-fibrotic action. Current scientific evidence supports that inhibition of ACE2 causes enhanced fibrosis. ACE2 is also the primary receptor that facilitates the entry of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. COVID-19 is associated with a myriad of symptoms ranging from asymptomatic to severe pneumonia and acute respiratory distress syndrome (ARDS) leading to respiratory failure, mechanical ventilation, and often death. One of the potential complications in people who recover from COVID-19 is pulmonary fibrosis. Cigarette smoking is a risk factor for fibrotic lung diseases, including the idiopathic form of this disease (idiopathic pulmonary fibrosis), which has a prevalence of 41% to 83%. Cigarette smoke increases the expression of pulmonary ACE2 and is thought to alter susceptibility to COVID-19. Cannabis is another popular combustible product that shares some similarities with cigarette smoke, however, cannabis contains cannabinoids that may reduce inflammation and/or ACE2 levels. The role of cannabis smoke in the pathogenesis of pulmonary fibrosis remains unknown. This review aimed to characterize the ACE2-Ang-(1–7)-MasR Axis in the context of pulmonary fibrosis with an emphasis on risk factors, including the SARS-CoV-2 virus and exposure to environmental toxicants. In the context of the pandemic, there is a dire need for an understanding of pulmonary fibrotic events. More research is needed to understand the interplay between ACE2, pulmonary fibrosis, and susceptibility to coronavirus infection.
- 30 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (23) , 12955
Open AccessInvolvement of the ACE2/Ang-(1–7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19
Pulmonary fibrosis is a chronic, fibrotic lung disease affecting 3 million people worldwide. The ACE2/Ang-(1–7)/MasR axis is of interest in pulmonary fibrosis due to evidence of its anti-fibrotic action. Current scientific evidence supports that inhibition of ACE2 causes enhanced fibrosis. ACE2 is also the primary receptor that facilitates the entry of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. COVID-19 is associated with a myriad of symptoms ranging from asymptomatic to severe pneumonia and acute respiratory distress syndrome (ARDS) leading to respiratory failure, mechanical ventilation, and often death. One of the potential complications in people who recover from COVID-19 is pulmonary fibrosis. Cigarette smoking is a risk factor for fibrotic lung diseases, including the idiopathic form of this disease (idiopathic pulmonary fibrosis), which has a prevalence of 41% to 83%. Cigarette smoke increases the expression of pulmonary ACE2 and is thought to alter susceptibility to COVID-19. Cannabis is another popular combustible product that shares some similarities with cigarette smoke, however, cannabis contains cannabinoids that may reduce inflammation and/or ACE2 levels. The role of cannabis smoke in the pathogenesis of pulmonary fibrosis remains unknown. This review aimed to characterize the ACE2-Ang-(1–7)-MasR Axis in the context of pulmonary fibrosis with an emphasis on risk factors, including the SARS-CoV-2 virus and exposure to environmental toxicants. In the context of the pandemic, there is a dire need for an understanding of pulmonary fibrotic events. More research is needed to understand the interplay between ACE2, pulmonary fibrosis, and susceptibility to coronavirus infection.
- Open Access
- 4 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11963
Aberrant Post-Transcriptional Regulation of Protein Expression in the Development of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is an incurable and prevalent respiratory disorder that is characterized by chronic inflammation and emphysema. COPD is primarily caused by cigarette smoke (CS). CS alters numerous cellular processes, including the post-transcriptional regulation of mRNAs. The identification of RNA-binding proteins (RBPs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) as main factors engaged in the regulation of RNA biology opens the door to understanding their role in coordinating physiological cellular processes. Dysregulation of post-transcriptional regulation by foreign particles in CS may lead to the development of diseases such as COPD. Here we review current knowledge about post-transcriptional events that may be involved in the pathogenesis of COPD.
- 4 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11963
Open AccessAberrant Post-Transcriptional Regulation of Protein Expression in the Development of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is an incurable and prevalent respiratory disorder that is characterized by chronic inflammation and emphysema. COPD is primarily caused by cigarette smoke (CS). CS alters numerous cellular processes, including the post-transcriptional regulation of mRNAs. The identification of RNA-binding proteins (RBPs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) as main factors engaged in the regulation of RNA biology opens the door to understanding their role in coordinating physiological cellular processes. Dysregulation of post-transcriptional regulation by foreign particles in CS may lead to the development of diseases such as COPD. Here we review current knowledge about post-transcriptional events that may be involved in the pathogenesis of COPD.
- Open Access
- 15 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3495
Inhalation Toxicology of Vaping Products and Implications for Pulmonary Health
E-cigarettes have a liquid that may contain flavors, solvents, and nicotine. Heating this liquid generates an aerosol that is inhaled into the lungs in a process commonly referred to as vaping. E-cigarette devices can also contain cannabis-based products including tetrahydrocannabinol (THC), the psychoactive component of cannabis (marijuana). E-cigarette use has rapidly increased among current and former smokers as well as youth who have never smoked. The long-term health effects are unknown, and emerging preclinical and clinical studies suggest that e-cigarettes may not be harmless and can cause cellular alterations analogous to traditional tobacco smoke. Here, we review the historical context and the components of e-cigarettes and discuss toxicological similarities and differences between cigarette smoke and e-cigarette aerosol, with specific reference to adverse respiratory outcomes. Finally, we outline possible clinical disorders associated with vaping on pulmonary health and the recent escalation of acute lung injuries, which led to the declaration of the vaping product use-associated lung injury (EVALI) outbreak. It is clear there is much about vaping that is not understood. Consequently, until more is known about the health effects of vaping, individual factors that need to be taken into consideration include age, current and prior use of combustible tobacco products, and whether the user has preexisting lung conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- 15 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3495
Open AccessInhalation Toxicology of Vaping Products and Implications for Pulmonary Health
E-cigarettes have a liquid that may contain flavors, solvents, and nicotine. Heating this liquid generates an aerosol that is inhaled into the lungs in a process commonly referred to as vaping. E-cigarette devices can also contain cannabis-based products including tetrahydrocannabinol (THC), the psychoactive component of cannabis (marijuana). E-cigarette use has rapidly increased among current and former smokers as well as youth who have never smoked. The long-term health effects are unknown, and emerging preclinical and clinical studies suggest that e-cigarettes may not be harmless and can cause cellular alterations analogous to traditional tobacco smoke. Here, we review the historical context and the components of e-cigarettes and discuss toxicological similarities and differences between cigarette smoke and e-cigarette aerosol, with specific reference to adverse respiratory outcomes. Finally, we outline possible clinical disorders associated with vaping on pulmonary health and the recent escalation of acute lung injuries, which led to the declaration of the vaping product use-associated lung injury (EVALI) outbreak. It is clear there is much about vaping that is not understood. Consequently, until more is known about the health effects of vaping, individual factors that need to be taken into consideration include age, current and prior use of combustible tobacco products, and whether the user has preexisting lung conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Open Access
- 5 December 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3882
The Aryl Hydrocarbon Receptor and the Maintenance of Lung Health
Much of what is known about the Aryl Hydrocarbon Receptor (AhR) centers on its ability to mediate the deleterious effects of the environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin). However, the AhR is both ubiquitously-expressed and evolutionarily-conserved, suggesting that it evolved for purposes beyond strictly mediating responses to man-made environmental toxicants. There is growing evidence that the AhR is required for the maintenance of health, as it is implicated in physiological processes such as xenobiotic metabolism, organ development and immunity. Dysregulation of AhR expression and activity is also associated with a variety of disease states, particularly those at barrier organs such as the skin, gut and lungs. The lungs are particularly vulnerable to inhaled toxicants such as cigarette smoke. However, the role of the AhR in diseases such as chronic obstructive pulmonary disease (COPD)—a respiratory illness caused predominately by cigarette smoking—and lung cancer remains largely unexplored. This review will discuss the growing body of literature that provides evidence that the AhR protects the lungs against the damaging effects of cigarette smoke.
- 5 December 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3882
Open AccessThe Aryl Hydrocarbon Receptor and the Maintenance of Lung Health
Much of what is known about the Aryl Hydrocarbon Receptor (AhR) centers on its ability to mediate the deleterious effects of the environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin). However, the AhR is both ubiquitously-expressed and evolutionarily-conserved, suggesting that it evolved for purposes beyond strictly mediating responses to man-made environmental toxicants. There is growing evidence that the AhR is required for the maintenance of health, as it is implicated in physiological processes such as xenobiotic metabolism, organ development and immunity. Dysregulation of AhR expression and activity is also associated with a variety of disease states, particularly those at barrier organs such as the skin, gut and lungs. The lungs are particularly vulnerable to inhaled toxicants such as cigarette smoke. However, the role of the AhR in diseases such as chronic obstructive pulmonary disease (COPD)—a respiratory illness caused predominately by cigarette smoking—and lung cancer remains largely unexplored. This review will discuss the growing body of literature that provides evidence that the AhR protects the lungs against the damaging effects of cigarette smoke.